KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Gains from Investment Securities (2016 - 2025)

Arbutus Biopharma's Gains from Investment Securities history spans 16 years, with the latest figure at $227000.0 for Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 34.01% year-over-year to $227000.0; the TTM value through Sep 2025 reached $2.7 million, up 269.66%, while the annual FY2024 figure was $2.6 million, 13025.0% up from the prior year.
  • Gains from Investment Securities for Q3 2025 was $227000.0 at Arbutus Biopharma, down from $300000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.9 million in Q4 2024 and bottomed at -$636000.0 in Q2 2023.
  • The 5-year median for Gains from Investment Securities is $219000.0 (2024), against an average of $296888.9.
  • The largest annual shift saw Gains from Investment Securities surged 613.33% in 2021 before it tumbled 405.77% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $193000.0 in 2021, then plummeted by 110.36% to -$20000.0 in 2022, then surged by 2015.0% to $383000.0 in 2023, then skyrocketed by 393.47% to $1.9 million in 2024, then plummeted by 87.99% to $227000.0 in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Gains from Investment Securities are $227000.0 (Q3 2025), $300000.0 (Q2 2025), and $300000.0 (Q1 2025).